Clinical trial NCT01857908: A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer (Adenocarcinoma)
Keywords: Adenocarcinoma
Abiraterone
Abiraterone Acetate
Zytiga
Correlative study
Castrate Resistant Prostate Cancer
Abiraterone Correlative study
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2013-05-20
Enrollment: 20
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving Abiraterone Acetate for Castrate Resistant Prostate Cancer

Brief summary: Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate treatment, particularly at the time of progression. Biomarkers may also help identify pathways to resistance of abiraterone acetate treatment. The most practical way of approaching this question is to explore surrogate biomarkers of prostate cancer including quantification of pharmacodynamic endocrine biomarkers.

Detailed description: Goals of this study include:

* Explore which circulating endocrine markers or endocrine related markers have the best potential to predict clinical response to abiraterone acetate in CRPC patients
* Explore the utility of microRNA, circulating DNA and exosome analyses in complementing the previous objective

Eligibility criteria: Inclusion Criteria:

* Signed written informed consent. Before any study procedures are performed, subjects (or their legally acceptable representatives) will have the details of the study described to them, and they will be given a written informed consent document to read. If subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of study personnel
* Be suitable for receiving treatment with abiraterone acetate and prednisone
* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
* Patients may not receive any other investigational agent or dose escalation of abiraterone acetate during study participation
* Patient consents to comply to treatment with abiraterone acetate as directed by their physician

Exclusion Criteria:

* Taking a dose of abiraterone acetate other than 1g daily or lack of compliance to daily dosing of abiraterone acetate and prednisone
* Patients receiving spironolactone or any other steroidogenic compounds in excess of the associated prednisone 5mg bid are excluded due to the potential for androgen receptor agonism

Primary outcomes:
measure: PSA
timeFrame: Patients will be followed from Day 1 (date of initiation of Abiraterone treatment) until the date of first documented progression (estimated to be 1 year). PSA will be assessed every 30 days (approximately) until the time of PSA/clinical progression
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Cancer Agency
state: British Columbia
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: Princess Margaret Cancer Centre
name: Anthony Joshua, BSc(Med) MBBS PhD FRACP
role: PRINCIPAL_INVESTIGATOR
affiliation: British Columbia Cancer Agency
name: Bernie Eigl, MD
role: PRINCIPAL_INVESTIGATOR
References: